Skip to Content

'
Betul Oran, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Medical Director, Unrelated Donor Program, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
Unit 0423
Unit Number: 423
Houston, TX 77030
Room Number: FC5.2018

Education & Training

Degree-Granting Education

2004 Boston University School of Public Health, Boston, MA, MS, Epidemiology
1995 Hacettepe University, Ankara, Turkey, MD, Medicine

Postgraduate Training

1/2006-2/2008 Internal Medicine Residency, Boston University, Boston, MA
11/2004-11/2005 Blood and Marrow Transplantation Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX
11/2001-11/2004 Hematology and Oncology Fellowship, Boston University, Boston, MA
6/2001-11/2001 Oncology Fellowship, Hacettepe, Ankara, Turkey

Board Certifications

2011 American Board of Hematology
2009 American Board of Internal Medicine
2001 Turkish Board of Internal Medicine

Experience/Service

Academic Appointments

Assistant Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2012-8/2015

Selected Publications

Peer-Reviewed Original Research Articles

1. Oran B, Cao K, Saliba RM, Rezvani K, de Lima M, Ahmed S, Hosing CM, Popat UR, Carmazzi Y, Kebriaei P, Nieto Y, Rondon G, Willis D, Shah N, Parmar S, Olson A, Moore B, Marin D, Mehta R, Fernández-Viña M, Champlin RE, Shpall EJ. BETTER ALLELE-LEVEL MATCHING IMPROVES TRANSPLANT RELATED MORTALITY AFTER DOUBLE CORD BLOOD TRANSPLANTATION. Haematologica. e-Pub 8/6/2015. PMID: 26250579.
2. Lee HC, Saliba RM, Rondon G, Chen J, Charafeddine Y, Medeiros LJ, Alatrash G, Andersson BS, Popat U, Kebriaei P, Ciurea S, Oran B, Shpall E, Champlin R. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. Biol Blood Marrow Transplant. e-Pub 7/14/2015. PMID: 26183077.
3. Thompson PA, Rezvani K, Hosing CM, Oran B, Olson AL, Popat UR, Alousi AM, Shah ND, Parmar S, Bollard C, Hanley P, Kebriaei P, Cooper L, Kellner J, McNiece IK, Shpall EJ. Umbilical cord blood graft engineering: challenges and opportunities. Bone Marrow Transplant 50 Suppl 2:S55-62, 6/2015. PMID: 26039209.
4. Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJ. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood 125(19):2885-92, 5/7/2015. e-Pub 3/16/2015. PMCID: PMC4424412.
5. Oran B, Jimenez AM, De Lima M, Popat UR, Bassett R, Andersson BS, Borthakur G, Bashir Q, Chen J, Ciurea SO, Jabbour E, Cortes J, Kebriaei P, Khouri IF, Qazilbash MH, Ravandi F, Rondon G, Lu X, Shpall EJ, Champlin RE. Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. e-Pub 3/31/2015. PMID: 25840338.
6. El Fakih R, Fox P, Popat U, Nieto Y, Shah N, Parmar S, Oran B, Ciurea S, Kebriaei P, Hosing C, Ahmed S, Shah J, Orlowski R, Champlin R, Qazilbash M, Bashir Q. Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. Clin Lymphoma Myeloma Leuk. e-Pub 3/27/2015. PMID: 25963284.
7. Saliba RM, Rezvani K, Leen A, Jorgensen J, Shah N, Hosing C, Parmar S, Oran B, Olson A, Rondon G, Chen J, Martinez C, Hamdi A, Mehta RS, Chemaly RF, Saunders IM, Bollard CM, Shpall EJ. General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation. Biol Blood Marrow Transplant. e-Pub 2/20/2015. PMID: 25708219.
8. Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, Jones R, Shpall EJ, Khouri I, Qazilbash M, Nieto Y, Shah N, Ahmed S, Oran B, Al Atrash G, Ciurea S, Kebriaei P, Chen J, Rondon G, Champlin R. Phase Ii Trial Of Gvhd Prophylaxis with Post-Transplantation Cyclophosphamide Following Reduced-Intensity Busulfan/Fludarabine (Bu/Flu) Conditioning for Hematological Malignancies. Biol Blood Marrow Transplant. e-Pub 2/7/2015. PMID: 25667989.
9. Kongtim P, Di Stasi A, Rondon G, Chen J, Adekola K, Popat U, Oran B, Kebriaei P, Andersson BS, Champlin RE, Ciurea SO. Can a Female Donor for a Male Recipient Decrease the Relapse Rate for Patients With Acute Myeloid Leukemia Treated With Allogeneic Hematopoietic Stem Cell Transplantation? Biol Blood Marrow Transplant. e-Pub 12/2014. PMCID: PMCPMC4359638.
10. Munoz J, Shah N, Rezvani K, Hosing C, Bollard CM, Oran B, Olson A, Popat U, Molldrem J, McNiece IK, Shpall EJ. Concise review: umbilical cord blood transplantation: past, present, and future. Stem Cells Transl Med 3(12):1435-43, 12/2014. e-Pub 11/5/2014. PMCID: PMC4250219.
11. Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, Pingali SR, Konopleva M, Kongtim P, Alousi A, Qazilbash MH, Ahmed S, Bashir Q, Al-atrash G, Oran B, Hosing CM, Kebriaei P, Popat U, Shpall EJ, Lee DA, de Lima M, Rezvani K, Khouri IF, Champlin RE, Ciurea SO. Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen-Matched Unrelated and Related Donors. Biol Blood Marrow Transplant 20(12):1975-81, 12/2014. e-Pub 9/2014. PMCID: PMCPMC4343203.
12. Khouri IF, Wei W, Korbling M, Turturro F, Ahmed S, Alousi A, Anderlini P, Ciurea S, Jabbour E, Oran B, Popat UR, Rondon G, Bassett RL, Gulbis A. BFR (bendamustine, fludarabine and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced risk of myelosuppression and severe graft-versus-host disease. Blood 124(14):2306-12, 10/2014. e-Pub 8/2014. PMCID: PMC4260365.
13. Oran B, Kongtim P, Popat U, de Lima M, Jabbour E, Lu X, Chen J, Rondon G, Kebriaei P, Ahmed S, Andersson B, Alousi A, Ciurea S, Shpall E, Champlin RE. Cytogenetics, Donor Type and use of Hypomethylating Agents in Myelodysplastic Syndrome with Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 20(10):1618-25, 10/2014. e-Pub 6/2014. PMID: 24953017.
14. Bejanyan N, Oran B, Shanley R, Warlick E, Ustun C, Vercellotti G, Verneris M, Wagner JE, Weisdorf D, Brunstein C. Clinical outcomes of AML patients relapsing after matched-related donor and umbilical cord blood transplantation. Bone Marrow Transplant 49(8):1029-35, 8/2014. e-Pub 6/2014. PMID: 24887379.
15. Bear AS, Hanley PJ, Bosque DM, Cruz CR, Kaur I, Liu H, Kebriaei P, Hosing C, Rezvani K, Oran B, De Lima MJ, Bollard CM, Shpall EJ. Low rate of infusional toxicity after expanded cord blood transplantation. Cytotherapy 16(8):1153-7, 8/2014. e-Pub 2/2014. PMCID: PMC4087060.
16. Arslan D, Guvenc O, Cimen D, Ulu H, Oran B. Prolonged QT dispersion in the infants of diabetic mothers. Pediatr Cardiol 35(6):1052-6, 8/2014. e-Pub 4/2014. PMID: 24740627.
17. Jabbour E, Daver N, Champlin R, Mathisen M, Oran B, Ciurea S, Khouri I, Cornelison AM, Ghanem H, Cardenas-Turanzas M, Popat U, Ravandi F, Giralt S, Garcia-Manero G, Cortes J, Kantarjian H, de Lima M. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. Am J Hematol 89(4):395-8, 4/2014. e-Pub 3/2014. PMCID: PMC4140180.
18. Bachanova V, Marks DI, Zhang MJ, Wang H, de Lima M, Aljurf MD, Arellano M, Artz AS, Bacher U, Cahn JY, Chen YB, Copelan EA, Drobyski WR, Gale RP, Greer JP, Gupta V, Hale GA, Kebriaei P, Lazarus HM, Lewis ID, Lewis VA, Liesveld JL, Litzow MR, Loren AW, Miller AM, Norkin M, Oran B, Pidala J, Rowe JM, Savani BN, Saber W, Vij R, Waller EK, Wiernik PH, Weisdorf DJ. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. Leukemia 28(3):658-65, 3/2014. e-Pub 8/2013. PMCID: PMC3951192.
19. Mehta RS, Di Stasi A, Andersson BS, Nieto Y, Jones R, de Lima M, Hosing C, Popat U, Kebriaei P, Oran B, Alousi A, Rezvani K, Qazilbash M, Bashir Q, Bollard C, Cooper L, Worth L, Tewari P, McNiece I, Willhelm K, Champlin R, Shpall EJ. The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation. Clin Lymphoma Myeloma Leuk 14(1):e1-5, 2/2014. e-Pub 10/2013. PMCID: PMC3913126.
20. Ustun C, Wiseman AC, Defor TE, Yohe S, Linden MA, Oran B, Burke M, Warlick E, Miller JS, Weisdorf D. Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML. Bone Marrow Transplant 48(11):1415-20, 11/2013. e-Pub 8/2013. PMID: 23933764.
21. Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MH. A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. Biol Blood Marrow Transplant 19(10):1453-8, 10/2013. e-Pub 7/2013. PMCID: PMC4157818.
22. Chakhachiro ZI, Saliba RM, Okoroji GJ, Korbling M, Alousi AM, Oran B, Anderlini P, Ciurea SO, Popat U, Champlin R, Samuels BI, Medeiros LJ, Bueso-Ramos C, Khouri IF. Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission. Cancer 119(18):3318-25, 9/2013. e-Pub 6/2013. PMCID: PMCPMC4371592.
23. Jabbour E, Mathisen MS, Garcia-Manero G, Champlin R, Popat U, Khouri I, Giralt S, Kadia T, Chen J, Pierce S, Koca E, Daver N, Tanaka M, Rondon G, Oran B, Parmar S, Kantarjian H, de Lima M. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: A retrospective case-control study. Am J Hematol 88(3):198-200, 3/2013. e-Pub 1/2013. PMCID: PMC4085133.
24. Aung FM, Lichtiger B, Bassett R, Liu P, Alousi A, Bashier Q, Ciurea SO, de Lima MJ, Hosing C, Kebriaei P, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Khouri I, Champlin RE, Popat U. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol 160(6):798-805, 3/2013. e-Pub 1/2013. PMCID: PMC4078723.
25. Oran B, Popat U, Rondon G, Ravandi F, Garcia-Manero G, Abruzzo L, Andersson BS, Bashir Q, Chen J, Kebriaei P, Khouri IF, Koca E, Qazilbash MH, Champlin R, de Lima M. Significance of Persistent Cytogenetic Abnormalities at Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission. Biol Blood Marrow Transplant 19(2):214-20, 2/2013. e-Pub 9/2012. PMCID: PMC4106407.
26. de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 367(24):2305-15, 12/2012. PMCID: PMC3805360.
27. Oran B, Weisdorf DJ. Survival for older patients with AML: a population based study. Haematologica 97(12):1916-24, 12/2012. e-Pub 7/2012. PMCID: PMC3590098.
28. Majhail NS, Brunstein CG, Shanley R, Sandhu K, McClune B, Oran B, Warlick ED, Wagner JE, Weisdorf DJ. Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors. Bone Marrow Transplant 47(4):494-8, 4/2012. e-Pub 5/2011. PMCID: PMC4107640.
29. Oran B, Wagner JE, DeFor TE, Weisdorf DJ, Brunstein CG. Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation. Biol Blood Marrow Transplant 17(9):1327-34, 9/2011. e-Pub 1/2011. PMCID: PMCPMC4130206.
30. Warlick ED, Tomblyn M, Cao Q, Defor T, Blazar BR, Macmillan M, Verneris M, Wagner J, Dusenbery K, Aurora M, Bachanova V, Brunstein C, Burns L, Cooley S, Kaufman D, Majhail NS, McClune B, McGlave P, Miller J, Oran B, Slungaard A, Vercellotti G, Weisdorf DJ. Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant 17(7):1025-32, 7/2011. e-Pub 11/2010. PMCID: PMCPMC4082980.
31. McCormack SE, Cao Q, Oran B, Weisdorf DJ, Warlick ED. Pre-transplant consolidation chemotherapy may not improve outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission. Leuk Res 35(6):757-61, 6/2011. e-Pub 1/2011. PMID: 21232793.
32. Oran B, Dolan M, Cao Q, Brunstein C, Warlick E, Weisdorf D. Monosomal karyotype provides better prognostic prediction after allogeneic stem cell transplantation in patients with acute myelogenous leukemia. Biol Blood Marrow Transplant 17(3):356-64, 3/2011. e-Pub 5/2010. PMID: 20553926.
33. Rosenzweig M, Seldin DC, Remick DG, Skinner M, Quillen K, Oran B, Finn KT, Sanchorawala V. Febrile reactions occurring with second cycle of high-dose melphalan and SCT in patients with AL amyloidosis: a 'melphalan recall' reaction. Bone Marrow Transplant 45(1):21-4, 1/2010. e-Pub 5/2009. PMCID: PMC3672063.
34. van Besien K, Kunavakkam R, Rondon G, De Lima M, Artz A, Oran B, Giralt S. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant 15(5):610-7, 5/2009. PMID: 19361753.
35. Saliba RM, Komanduri KV, Giralt S, de Souza J, Patah P, Oran B, Couriel D, Rondon G, Champlin RE, de Lima M. Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML. Bone Marrow Transplant 43(9):685-92, 5/2009. e-Pub 11/2008. PMCID: PMCPMC4038152.
36. Tam M, Seldin DC, Forbes BM, Connors LH, Skinner M, Oran B, Quillen K, Sanchorawala V. Spontaneous rupture of the liver in a patient with systemic AL amyloidosis undergoing treatment with high-dose melphalan and autologous stem cell transplantation: a case report with literature review. Amyloid 16(2):103-7, 2009. PMCID: PMC2911629.
37. Oran B, Giralt S, Couriel D, Hosing C, Shpall EJ, de Meis E, Khouri IF, Qazilbash M, Anderlini P, Kebriaei P, Popat U, Carrasco-Yalan A, Champlin RE, de Lima M. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia 21(12):2540-4, 12/2007. e-Pub 7/5/2007. PMID: 17611563.
38. Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I, Couriel D, Qazilbash M, Anderlini P, Kebriaei P, Ghosh S, Carrasco-Yalan A, de Meis E, Anagnostopoulos A, Donato M, Champlin RE, de Lima M. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 13(4):454-62, 4/2007. e-Pub 2/8/2007. PMID: 17382251.
39. Oran B, Donato M, Aleman A, Hosing C, Korbling M, Detry MA, Wei C, Anderlini P, Popat U, Shpall E, Giralt S, Champlin RE. Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment. Biol Blood Marrow Transplant 13(4):469-77, 4/2007. e-Pub 2/2007. PMID: 17382253.
40. Seldin DC, Anderson JJ, Skinner M, Malek K, Wright DG, Quillen K, Finn K, Oran B, Sanchorawala V. Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. Blood 108(12):3945-7, 12/1/2006. e-Pub 8/22/2006. PMCID: PMC1895463.
41. Lee HJ, Oran B, Saliba RM, Couriel DM, Shin K, Massey P, Neumann J, de Lima M, Champlin R, Giralt S. Steroid myopathy in patients with acute graft-versus-host disease treated with high-dose steroid therapy. Bone Marrow Transplant 38(4):299-303, 8/2006. e-Pub 7/3/2006. PMID: 16819437.
42. Oran B, Malek K, Sanchorawala V, Wright DG, Quillen K, Finn KT, La Valley M, Skinner M, Seldin DC. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplant 35(6):567-75, 3/2005. PMID: 15665842.
43. Erman M, Abali H, Oran B, Haznedaroglu IC, Canpinar H, Kirazli S, Celik I. Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state? Ann Oncol 15(11):1622-6, 11/2004. PMID: 15520062.
44. Oran B, Lee-Parritz A, Ansell J. Low molecular weight heparin for the prophylaxis of thromboembolism in women with prosthetic mechanical heart valves during pregnancy. Thromb Haemost 92(4):747-51, 10/2004. PMID: 15467905.
45. Oran B, Celik I, Erman M, Baltali E, Zengin N, Demirkazik F, Tezcan S. Analysis of menstrual, reproductive, and life-style factors for breast cancer risk in Turkish women: a case-control study. Med Oncol 21(1):31-40, 2004. PMID: 15034211.
46. Oran B, Wright DG, Seldin DC, McAneny D, Skinner M, Sanchorawala V. Spontaneous rupture of the spleen in AL amyloidosis. Am J Hematol 74(2):131-5, 10/2003. PMID: 14508801.
47. Cobankara V, Oran B, Ozatli D, Haznedaroglu IC, Kosar A, Buyukasik Y, Ozcebe O, Dundar S, Kirazli S. Cytokines, endothelium, and adhesive molecules in pathologic thrombopoiesis. Clin Appl Thromb Hemost 7(2):126-30, 4/2001. PMID: 11292190.

Invited Articles

1. Oran B, Popat U, Andersson B, Champlin R. Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk 13 Suppl 2:S282-8, 9/2013. PMID: 24290213.
2. Oran B. Can double-cord transplants provide a more potent graft-vs-leukemia effect? Best Pract Res Clin Haematol 25(4):479-82, 12/2012. e-Pub 11/4/2012. PMID: 23200545.
3. Oran B, Shpall E. Umbilical cord blood transplantation: a maturing technology. Hematology Am Soc Hematol Educ Program 2012:215-22, 2012. PMID: 23233584.
4. Oran B, Weisdorf DJ. Allogeneic stem cell transplantation in first complete remission. Curr Opin Hematol 18(6):395-400, 11/2011. NIHMSID: NIHMS348482.
5. Oran B, de Lima M. Prevention and treatment of acute myeloid leukemia relapse after allogeneic stem cell transplantation. Curr Opin Hematol 18(6):388-94, 11/2011. PMID: 21897227.

Editorials

1. Oran B, Shpall EJ. Allele-Level HLA Cord Blood Matching Matters. Blood 123(1):8-9, 1/2/2014. PMID: 24385496.

Abstracts

1. Popat U, Saliba R, Oran B, Chen J, Alousi A, Ahmed S, Bashir Q, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Nieto Y, Olson A, Parmar S, Shah N, Shpall E, Qazilbash M, Andersson B, Champlin R. Cytogenetics and Blast Count Determine Transplant Outcomes in Advanced AML. Biology of Blood and Marrow Transplantation 21(2), 2/2015.
2. Hosing C, Munsell M, Armitage S, Sadeghi T, Rezvani K, Oran B, Marin D, Dworsky S, Popat U, Wilson J, Alousi A, Shah N, Olson A, Jones R, Kebriaei P, Qazilbash M, McNiece I, Parmar S, Champlin R, Shpall E. Ex-Utero Plus in Utero Collection of Umbilical Cord Blood (CB) for Banking Yields Higher Total Nucleated Cell Counts (TNC) Compared to Either Procedure Alone. Biology of Blood and Marrow Transplantation 21(2), 2/2015.
3. Gaballa S, Saliba R, Oran B, Brammer J, Chen J, Rondon G, Alousi A, Kebriaei P, Popat U, Andersson B, Shpall E, Jabbour E, Daver N, Andreeff M, Ravandi F, Cortes J, Champlin R, Ciurea S. Minimal Residual Disease By PCR Testing Is a Significant Predictor of Disease Relapse in Patients with FLT3 Positive AML after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 21(2), 2/2015.
4. Thompson P, Perera T,Marin D, Oran B, Popat U, Qazilbash M, Shah N, Parmar S, Rezvani K, Olson A, Kebriaei P, Rondon G, Alousi A, Ciurea S, Champlin R, Bajel A, Szer J, Shpall E, Ritchie D, Hosing C. Results of Allogeneic Double Umbilical Cord Blood Transplantation for Relapsed and Refractory Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation 21(2), 2/2015.
5. Uday R. Popat, Rima Saliba, Betul Oran, Julianne Chen, Amin M. Alousi, Sairah Ahmed, Qaiser Bashir, Stefan O. Ciurea, Chitra Hosing, Roy B. Jones, Partow Kebriaei, Issa F. Khouri, Yago L. Nieto, Amanda Olson, Simrit Parmar, Nina Shah, Elizabeth J. Shpall, Muzaffar H. Qazilbash, Borje S. Andersson, Richard E. Champlin. Cytogenetics and Blast Count Determine Transplant Outcomes in Advanced AML. ASBMT 2015, 2015.
6. Muhamed Baljevic, Kai Cao, Richard E. Champlin, Uday R. Popat, Chitra Hosing, Nina Shah, Simrit Parmar, Katy Rezvani, Amanda Olson, Elizabeth J. Shpall, Betul Oran. Dual Donor T-Cell Chimerism Does Not Predict Poor Prognosis after Double Cord Blood Allogeneic Transplantation. ASBMT 2015, 2015.
7. Chitra Hosing, MD, Mark Munsell, Sue Armitage, Tara Sadeghi, Katy Rezvani, MD, Betul Oran, MD, David Marin, Suzanne Dworsky, Uday R. Popat, MD, Jeffrey Wilson, Amin M. Alousi, MD, Nina Shah, MD, Amanda Olson, M.D., Roy B. Jones, MD, PhD, Partow Kebriaei, MD, Muzaffar H. Qazilbash, MD, Simrit Parmar, MD, Ian McNiece, PhD, Richard E. Champlin, MD, Elizabeth J. Shpall, MD. Ex-Utero Plus in Utero Collection of Umbilical Cord Blood (CB) for Banking Yields Higher Total Nucleated Cell Counts (TNC) Compared to Either Procedure Alone. ASBMT, 2015.
8. Sameh Gaballa, Rima Saliba, Betul Oran, Jonathan E. Brammer, Julianne Chen, Gabriela Rondon, Amin M. Alousi, Partow Kebriaei, Uday R. Popat, Borje S. Andersson, Elizabeth J. Shpall, Elias Jabbour, Naval Daver, Michael Andreeff, Farhad Ravandi, Jorge Cortes, Richard E. Champlin, Stefan O. Ciurea. Minimal Residual Disease By PCR Testing Is a Significant Predictor of Disease Relapse in Patients with FLT3 Positive AML after Hematopoietic Stem Cell Transplantation. ASBMT 2015, 2015.
9. Philip A. Thompson, Travis Perera, David Marin, Betul Oran, Uday R. Popat, Muzaffar H. Qazilbash, Nina Shah, Simrit Parmar, Katy Rezvani, Amanda Olson, Partow Kebriaei, Gabriela Rondon, Amin M. Alousi, Stefan O. Ciurea, Richard E. Champlin, Ashish Bajel, Jeffrey Szer, Elizabeth J. Shpall, David Stuart Ritchie, Chitra Hosing. Results of Allogeneic Double Umbilical Cord Blood Transplantation for Relapsed and Refractory Hodgkin Lymphoma. ASBMT 2015, 2015.
10. Roni Tamari, MD, Betul Oran, MD, Patrick Hilden, MS, Esperanza B Papadopoulos, MD, Piyanuch Kongtim, MD, Gabriela Rondon, MD, Ann A. Jakubowski, MD, PhD, Borje S Andersson, MD, PhD, Sean M. Devlin, PhD, Sairah Ahmed, MD, James W. Young, MD, Uday R. Popat, MD, Julianne Chen, Marcos de Lima, MD, Richard J O'Reilly, MD, Sergio Giralt, MD, Richard E. Champlin and Hugo Castro-Malaspina, MD. Allo- HSCT for Advanced Myelodysplastic Syndrome:MSKCC Vs MDACC. Blood 124(21), 12/2014.
11. Brenda M. Sandmaier, MD, Samer K Khaled, MD, Betul Oran, MD, Guy Gammon, MD, Denise Trone and Olga Frankfurt, MD. Results of a Phase 1 Study of Quizartinib (AC220) As Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Remission Following Allogeneic Hematopoietic Cell Transplantation. Blood 124(21), 12/2014.
12. Betul Oran, MD, Richard E. Champlin, Jorge E. Cortes, Marcos de Lima, MD, Xuemei Wang, PhD, Hsiang-Chun Chen, Farhad Ravandi, MD, Stefan O. Ciurea, MD, Hagop M. Kantarjian, MD and Gautam Borthakur, MD. Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in First Remission Improves Outcome Irrespective of FLT3-ITD Allelic Burden Among Patients with Acute Myeloid Leukemia and FLT3-ITD Mutation. Blood 124(21), 12/2014.
13. Sairah Ahmed, MD, Elizabeth J Shpall, MD, Alison Gulbis, Roy Jones, Charles S. Martinez, Gabriela Rondon, MD, Katayoun Rezvani, Betul Oran, MD, Amanda Olson, Nina Shah, Simrit Parmar, Uday R. Popat, MD, Amin M. Alousi, MD, Yago Nieto, Chitra M. Hosing, Qaiser Bashir, Partow Kebriaei, Muzaffar H. Qazilbash, Richard E. Champlin and Victor E. Mulanovich. Assessment of Incidence Toxoplasma Gondii Infection and Outcomes in Allogeneic Stem Cell Patients. Blood 124(21), 12/2014.
14. Basem M. William, MD, Marcos de Lima, MD, Betul Oran, MD, Richard Champlin, MD, Esperanza B Papadopoulos, MD, Sergio Giralt, MD, Bart L. Scott, MD, Joel Hetzer, PhD, Xiwei Wang, PhD, Eric Laille, MS, Barry S. Skikne, MD and Charles Craddock, MD PhD. CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML). Blood 124(21), 12/2014.
15. Monica Cabrero, MD, Guillermo Garcia-Manero, MD, Koji Sasaki, Naval Daver, MD, Gautam Borthakur, MD, Courtney D. DiNardo, MD, Jorge Cortes, MD, Zach Bohannan, Victoria Sukholutsky, Farhad Ravandi, MD, Sherry Pierce, BSN, BA, Tapan M. Kadia, MD, Naveen Pemmaraju, MD, Betul Oran, MD, Richard E. Champlin, Hagop M. Kantarjian, MD and Elias Jabbour, MD. Comparison of Continuation of HMA Vs Allogeneic Stem Cell Transplant and Its Timing in Myelodysplastic Syndromes: Can It Wait? Results of a Retrospective Study. Blood 124(21), 12/2014.
16. Sameh Gaballa, M, Piyanuch Kongtim, MD, Gabriela Rondon, MD, Julianne Chen, Uday Popat, MD, Sairah Ahmed, MD, Chitra M Hosing, MD, Betul Oran, MD, Partow Kebriaei, MD, Simrit Parmar, MD, Nina Shah, MD, Issa F. Khouri, MD, Richard E. Champlin and Stefan O. Ciurea, MD. Feasibility and Outcomes of Haploidentical Transplantation for Elderly Patients with Advanced Hematological Malignancies: The MD Anderson Cancer Center Experience. Blood 124(21), 12/2014.
17. Betul Oran, MD, Kai Cao, MD, Rima M. Saliba, PhD, Chitra M. Hosing, Uday R. Popat, MD, Marcos de Lima, MD, Yudith Carmazzi, MS, Amin Alousi, MD, Partow Kebriaei, Yago Nieto, Gabriela Rondon, MD, Dana Willis, Nina Shah, Simrit Parmar, Amanda Olson, Brandt Moore, Richard E. Champlin, Katayoun Rezvani and Elizabeth J Shpall, MD. Higher Allele Level HLA Matching Improves Prognostication after Double Umbilical Cord Blood (dUCB) Transplantation for Hematological Malignancies. Blood 124(21), 12/2014.
18. Betul Oran, MD, Saliba M. Rima, MD, Borje S Andersson, MD, PhD, Marcos J de Lima, MD, Uday R. Popat, MD, Issa F. Khouri, MD, Partow Kebriaei, Qaiser Bashir, Sairah Ahmed, MD, Elizabeth J Shpall, MD, Richard E. Champlin and Gabriela Rondon, MD. Improved Progression-Free Survival with Minimal Toxicity after Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Hematological Malignancy. Blood 124(21), 12/2014.
19. Uday R. Popat, MD, Patricia S Fox, MS, Roland Bassett, Julianne Chen, Benigno C. Valdez, PhD, Jitesh Kawedia, Sairah Ahmed, MD, Amin M. Alousi, MD, Qaiser Bashir, Stefan O. Ciurea, MD, Chitra M. Hosing, Roy Jones, Partow Kebriaei, Issa F. Khouri, MD, Yago Nieto, Amanda Olson, Betul Oran, MD, Simrit Parmar, Muzaffar H. Qazilbash, MD, Nina Shah, Elizabeth J Shpall, MD, Borje S Andersson, MD, PhD and Richard E. Champlin. Myeloablative Timed Sequential Busulfan Is Safe in Older Patients. Blood 124(21) (#3859), 12/2014.
20. Issa F. Khouri, MD, Rima M Saliba, Ph.D, Zijun Y. Xu-Monette, PhD, Martin Korbling, MD, Gabriela Rondon, MD, Rosamar Valverde, Amin M. Alousi, MD, Paolo Anderlini, MD, Sairah Ahmed, MD, Stefan O Ciurea, MD, Luis Fayad, MD, Betul Oran, MD, Simrit Parmar, Uday R. Popat, MD, Jason R. Westin, MD, Francesco Turturro, MD, L. Jeffrey Medeiros, MD, Alison M Gulbis, PharmD, BCOP and Ken H. Young, MD, PhD. Outcomes Following Allogeneic Stem Cell Transplantation (AlloSCT) in Patients with Primary Mediastinal (PMBL), Germinal Center B (GCB) and Non-GCB Cell-like Diffuse Large B Cell Lymphomas (DLBCL). Blood 124(21), 12/2014.
21. Ghantoji SS, Goddu S, Sreenivasula S, Shah DP, Oran B, Rezvani K, Rondon G, Shpall EJ, Chemaly RF. Characteristics and Outcome of Cytomegalovirus (CMV) Infections in 95 Cord Blood Transplant (CBT) Recipients: The MD Anderson Experience. Biology of Blood and Marrow Transplantation 20(2), 2/2014.
22. Pingali, SR, Milton D, di Stasi A, Patel RD, Kebriaei P, Popat UR, Alousi AM, Anderlini P, Qazilbash MH, Hosing C, Rezvani K, Bashir Q, Oran B, Shpall EJ, Khouri IF, Champlin RE, Ciurea SO. Haploidentical Transplantation for Advanced Hematologic Malignancies Using Melphalan-Based Conditioning – Mature Results from a Single Center. Biology of Blood and Marrow Transplantation 20(2), 2/2014.
23. Adekola K, di Stasi A, Ferro R, Ahmed S, de Lima MJG, Oran B, Andersson BS, Quintas-Cardama A, Jabbour E, Kantarjian H, Cortes J, Champlin RE, Ciurea SO. Safety and Efficacy of Haploidentical Stem Cell Transplantation for Advanced Chronic Myeloid Leukemia. Biology of Blood and Marrow Transplantation 20(2), 2/2014.
24. Issa F. Khouri, MD, Wei Wei, MS, Rosamar Valverde, MD, Martin Korbling, MD, Francesco Turturro, MD, Alison M Gulbis, PharmD, BCOP, Maria Guillermo-Pacheco, Sairah Ahmed, MD, Amin Alousi, MD, Betul Oran, MD, Paolo Anderlini, MD, Stefan O Ciurea, MD, Chitra M. Hosing, MD, Uday R Popat, MD, Elias Jabbour, MD, Richard E Champlin, MD and Roland Bassett. Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning: A Novel Regimen Inducing Immunosuppression Without Myelosuppression. Blood 122(21), 11/2013.
25. Issa F. Khouri, MD, Rima M. Saliba, Ph.D., Pramoda Challagundla, Celina Ledesma, Martin Korbling, MD, Alison M Gulbis, PharmD, BCOP, Maria Guillermo-Pacheco, Sairah Ahmed, MD, Paolo Anderlini, MD, Qaiser Bashir, MD, Betul Oran, MD, Stefan O Ciurea, MD, Chitra M. Hosing, MD, Partow Kebriaei, MD, Uday R Popat, MD, Elias Jabbour, MD, Richard E Champlin, MD and Jeffrey L. Jorgensen, MD, PhD. Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis. Blood 122(21), 11/2013.
26. Betul Oran, MD, Michelle Poon, Julianne Chen, Gabriela Rondon, MD, Sairah Ahmed, MD, Borje S. Andersson, MD, PhD, Qaiser Bashir, MD, Stefan O. Ciurea, MD, Chitra M. Hosing, MD, Simrit Parmar, MD, Muzaffar H. Qazilbash, MD, Uday R Popat, MD, Yago Nieto, MD, PhD, Amin Alousi, MD, Roy B Jones, PhD MD, Katy Rezvani, MD, PhD, Marcos de Lima, MD, Elizabeth J Shpall, MD, Richard E Champlin, MD and Partow Kebriaei, MD. Comparable Outcomes After Sibling and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantations (HCT) In Adult Acute Lymphoblatic Leukemia (ALL) With First Complete Remission (CR). Blood 122(21), 11/2013.
27. Sairah Ahmed, MD, Antonio Di Stasi, MD, Elizabeth J. Shpall, M.D., Issa F. Khouri, MD, Amin M. Alousi, M.D., Stefan O. Ciurea, MD, Qaiser Bashir, MD, Muzaffar Qazilbash, M.D., Roy B. Jones, MD, PhD, Yago Nieto, MD, PhD, Simrit Parmar, MD, Partow Kebriaei, MD, Nina Shah, MD, Katy Rezvani, MD, PhD, Chitra M Hosing, MD, Betul Oran, MD, Michael Andreeff, MD, PhD, Paolo Anderlini, MD, Borje S Andersson, MD, PhD, Richard E Champlin, MD and Uday Popat, MD. Development of Donor Cell Derived Leukemia After Allogeneic Stem Cell Transplant. Blood 122(21), 11/2013.
28. Uday R Popat, MD, Betul Oran, MD, Chitra M. Hosing, MD, Partow Kebriaei, MD, Katy Rezvani, MD, PhD, Simrit Parmar, MD, Nina Shah, MD, Catherine M. Bollard, MBChB, MD, Jeffrey J. Molldrem, MD, Yago Nieto, MD, PhD, Borje S. Andersson, MD, PhD, Amin Alousi, MD, Roy B. Jones, MD, PhD, Laurence J N Cooper, MD, PhD, Muzaffar H. Qazilbash, MD, Qaiser Bashir, MD, Sairah Ahmed, MD, Doyle Bosque, ADN, Julianne Chen, Jessica McCarty, Gabriela Rondon, MD, Mark Munsell, Ian K. McNiece, PhD, Indreshpal Kaur, PhD, Eric Yvon, PhD, Katherine Annandale, Sarah Olchesky, Marcos J de Lima, MD, Richard E Champlin, MD, Leonard Miller, PhD, Linda Paradiso, DVM.MBA, Lynnet Koh, MS, MBA, Patrick A. Zweidler-McKay, MD/PhD and Elizabeth J Shpall, MD. Ex Vivo Fucosylation Of Cord Blood Accelerates Neutrophil and Platelet Engraftment. Blood 122(21), 11/2013.
29. Sai Ravi Pingali, MD, Milton Denai, M S, Antonio Di Stasi, MD, Partow Kebriaei, MD, Uday R Popat, MD, Amin Alousi, MD, Paolo Anderlini, MD, Simrit Parmar, MD, Chitra M. Hosing, MD, Borje S. Andersson, MD, PhD, Qaiser Bashir, MD, Sairah Ahmed, MD, Betul Oran, MD, Elizabeth J Shpall, MD, Issa Khouri, MD, Marina Konopleva, MD, PhD, Gheath Alatrash, D.O., Ph.D., Richard E Champlin, MD and Stefan O. Ciurea, MD. Haploidentical Transplantation For Patients With Advanced Hematologic Malignancies With Melphalan-Based Conditioning – Interim Results From a Phase II Clinical Trial. Blood 122(21), 11/2013.
30. Piyanuch Kongtim, MD, Uday R Popat, MD, Marcos de Lima, MD, Guillermo Garcia-Manero, MD, Elias J. Jabbour, MD, Juliane Chen, Gabriela Rondon, MD, Lynne V. Abruzzo, MD, PhD, Stefan O. Ciurea, MD, Elizabeth J Shpall, MD, Richard E Champlin, MD and Betul Oran, MD. MD Anderson Scoring System (MDACC) Predicts Outcomes After Hematopoietic Stem Cell Transplantation (HSCT) Better Than Other Prognostic Classifications In MDS. Blood 122(21), 11/2013.
31. Maliha Nusrat, MD, Syed M. Kazmi, MD, Amanda Megan Cornelison, MS, PA-C, Partow Kebriaei, MD, Yago Nieto, MD, PhD, Betul Oran, MD, Robert Z. Orlowski, M.D., Ph.D., Simrit Parmar, MD, Uday R Popat, MD, Jatin J. Shah, M.D., Nina Shah, MD, Richard E Champlin, MD, Muzaffar H. Qazilbash, MD and Qaiser Bashir, MD. Outcomes Among High Risk and Standard Risk Multiple Myeloma Patients Treated With High Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation. Blood 122(21), 11/2013.
32. Aditya Shetty, MD, Hagop M Kantarjian, MD, Richard E Champlin, MD, Gautam Borthakur, MD, Talha Badar, MBBS, FCPS (Medical Oncology), Guillermo Garcia-Manero, MD, Borje S. Andersson, MD, PhD, Betul Oran, MD, Stefan O. Ciurea, MD, Marina Konopleva, MD, PhD, Michael Andreeff, MD, PhD, Steven M. Kornblau, MD, William G. Wierda, MD, Sherry Pierce, Farhad Ravandi, MD and Jorge E. Cortes, MD. Survivorship In AML - Outcomes Of Acute Myelogenous Leukemia (AML) Patients (pts) After Maintaining Complete Remission (CR) For At Least 3 Years. Blood 122(21), 11/2013.
33. Armin Ghobadi, MD, Amir Hamdi, MD, Piyanuch Kongtim, MD, Denai Milton, Amin Alousi, MD, Paolo Anderlini, MD, Stefan O. Ciurea, MD, Betul Oran, MD, Issa Khouri, MD, Simrit Parmar, MD, Muzaffar H. Qazilbash, MD, Partow Kebriaei, MD, Uday R Popat, MD, Katy Rezvani, MD, PhD, Roy F Chemaly, MD, MPH, Elizabeth J Shpall, MD, Richard E Champlin, MD and Qaiser Bashir, MD. The Effect Of CMV Reactivation On Relapse and Survival In Patients With AML and MDS After Allogeneic Stem Cell Transplant (allo-HCT). Blood 122(21), 11/2013.
34. Antonio Di Stasi, MD, LM Poon, M.D., Roberto Ferro, MD, Denai Milton, Gabriela Rondon, MD, Sa A. Wang, MD, Amir Hamdi, MD, Muzaffar H. Qazilbash, MD, Sairah Ahmed, MD, Issa Khouri, MD, Betul Oran, MD, Chitra M. Hosing, MD, Partow Kebriaei, MD, Amin Alousi, MD, Uday R Popat, MD, Elizabeth J Shpall, MD, Dean A. Lee, MD, PhD, Katy Rezvani, MD, PhD, Richard E Champlin, MD and Stefan O. Ciurea, MD. Transplant Outcomes For Patients With AML/MDS Using Melphalan-Based Conditioning. Blood 122(21), 11/2013.
35. Oran B, Quing C, Brunstein C, Majhail N, Weisdorf D. Similar And Promising Outcomes In Older AML Patients In First Complete Remission After Reduced Intensity Conditioning With Cord Blood And Sibling Donor Transplantation. Biology of Blood and Marrow Transplantation 16(2):231-232, 2010.
36. Oran B, Dolan M, Ma L, Brunstein C, Warlick E, Weisdorf DJ. Monosomal Karyotype Provides Better Prognostic Prediction After Allogeneic Stem Cell Transplantation in AML Patients. Blood 114:525, 2009.
37. Rosenzweig M, Seldin DC, Remick DG, Skinner M, Quillen K, Oran B, Finn KT, Sanchorawala V. Febrile reactions occurring with a second cycle of high dose melphalan and SCT in patients with AL amyloidosis: a ‘melphalan recall’ reaction. Blood 112:1120, 2008.
38. Van Besien K, De Lima M, Artz A, Oran B, Stock W, Giralt S. Alemtuzumab Reduces Chronic Graft Versus Host Disease (cGVHD) and Treatment Related Mortality (TRM) after Reduced Intensity Conditioning for AML and MDS. Blood 110:1076, 2007.
39. Seldin DC, Skinner M, Oran B, Quillen K, Finn KT, Sanchorawala V. Relapse Rate and Long-Term Survival of AL Amyloidosis Patients Treated with High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT). Blood 108:3094, 2006.
40. Oran B, Aleman A, Shpall EJ, Hosing C, Korbling M, Anderlini P, Champlin R, donato M. Higher Rate of Thrombotic Thrombocytopenic Pupura (TTP) Associated with Graft Versus Host Disease (GVHD) and Unrelated Donor Bone Marrow Transplantation (BMT). Blood 106:1111, 2005.
41. Oran B, Saliba R, Giralt G, Couriel D, Carrasco-Yalan A, Hosing C, Shahjahan M, de Meis E, Anagnostopoulos A, Anderlini P, Ghosh S, Khouri I,. Champlin R, de Lima M. Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with Fludarabine and Melphalan (FM) Reduced Intensity Conditioning (RIC) for High-Risk AML/MDS. Blood 106:838, 2005.
42. Oran B, Giralt S, Shahjahan M, Anagnostopoulos A, Couriel D, Kebriaei P, Hosing C, Ghosh S, D Meis E, Donato M, Ativivas T, Carrasco-Yalan A, Champlin R, de Lima M. Natural History of AML / MDS Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Using Reduced Intensity (RIC) Preparative Regimens. Blood 106:2019, 2005.
43. Oran B, Hun L, de Lima M, Couriel D, MD, Giralt S , Saliba R. Steroid complications in patiensts with acute graft versus host disease. Blood 106:5338, 2005.
44. Betul Oran, MD, Piyanuch Kongtim, MD, Marcos de Lima, MD, Uday R Popat, MD, Guillermo Garcia-Manero, Elias J. Jabbour, MD, Lynne V. Abruzzo, MD, PhD, Julianne Chen, Gabriela Rondon, MD, Borje S. Andersson, MD, PhD, Amin Alousi, MD, Stefan O. Ciurea, MD, Elizabeth J Shpall, MD and Richard E Champlin, MD. Prior Hypomethylating Agents Or Chemotherapy Does Not Improve The Outcome Of Allogeneic Hematopoietic Transplantation For High Risk MDS. Journal of Clinical Oncology. Submitted.

Book Chapters

1. Rohtesh Mehta, Betul Oran, Elizabeth Shpall. Alternative Donor Transplant: Cord Blood Transplant. In: The M.D. Anderson Manual of Medical Oncology, 3rd Edition, 2015.

Last updated: 9/14/2015